Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine

References

• Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA289(2), 179–186 (2003).
   PubMed Web of Science ®Google Scholar
• Mullooly JP, Bridges CB, Thompson WW et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine25(5), 846–855 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA292(11), 1333–1340 (2004).
   PubMed Web of Science ®Google Scholar
• Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine25(27), 5086–5096 (2007).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Shay DK, Broder K et al. Prevention and control of seasonal influenza with vaccines, recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm. Rep.58(RR-8), 1–52 (2009).
   PubMedGoogle Scholar
• Hobson D, Curry RL, Beare AS, Ward-Gardner A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.)70(4), 767–777 (1972).
   PubMedGoogle Scholar
• Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br. Med. Bull.35(1), 69–75 (1979).
   PubMed Web of Science ®Google Scholar
• Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly, a quantitative review. Vaccine24(8), 1159–1169 (2006).
   PubMed Web of Science ®Google Scholar
• McElhaney JE, Ewen C, Zhou X et al. Granzyme B, correlates with protection and enhanced CTL response to influenza vaccination in older adults. Vaccine27(18), 2418–2425 (2009).
   PubMed Web of Science ®Google Scholar
• Murasko DM, Bernstein ED, Gardner EM et al. Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly. Exp. Gerontol.37(2–3), 427–439 (2002).
   PubMed Web of Science ®Google Scholar
• Feng J, Gulati U, Zhang X et al. Antibody quantity versus quality after influenza vaccination. Vaccine27(45), 6358–6362 (2009).
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Tweed SA, De Serres G. Rapid decline of influenza vaccine-induced antibody in the elderly, is it real, or is it relevant? J. Infect. Dis.197(4), 490–502 (2008).
   PubMed Web of Science ®Google Scholar
• Targonski PV, Jacobson RM, Poland GA. Immunosenescence: role and measurement in influenza vaccine response among the elderly. Vaccine25(16), 3066-3069 (2007).
   PubMed Web of Science ®Google Scholar
• Joshi SR, Shaw AC, Quagliarello VJ. Pandemic influenza H1N1 2009, innate immunity, and the impact of immunosenescence on influenza vaccine. Yale J. Biol. Med.82(4), 143–151 (2009).
   Google Scholar
• Sambhara S, McElhaney JE. Immunosenescence and influenza vaccine efficacy. Curr. Top. Microbiol. Immunol.333, 413–429 (2009).
   PubMedGoogle Scholar
• Panda A, Arjona A, Sapey E et al. Human innate immunosenescence, causes and consequences for immunity in old age. Trends Immunol.30(7), 325–333 (2009).
   PubMed Web of Science ®Google Scholar
• Burns EA. Effects of aging on immune function. J. Nutr. Health Aging8(1), 9–18 (2004).
   PubMedGoogle Scholar
• Panda A, Qian F, Mohanty S et al. Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J. Immunol.184(5), 2518–2527 (2010).
   PubMed Web of Science ®Google Scholar
• Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine26(Suppl. 4), D17–D22 (2008).
   PubMed Web of Science ®Google Scholar
• Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA272(21), 1661–1665 (1994).
   PubMed Web of Science ®Google Scholar
• Rivetti D, Jefferson T, Thomas R et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev.3, CD004876 (2006).
   PubMedGoogle Scholar
• Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine20, 1831–1836 (2002).
   PubMed Web of Science ®Google Scholar
• Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann. Intern. Med.123, 518–527 (1995).
   PubMed Web of Science ®Google Scholar
• Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int. J. Epidemiol.35(2), 337–344 (2006).
   PubMed Web of Science ®Google Scholar
• Simonsen L, Taylor RJ, Viboud C, Miller MA, Jackson LA. Mortality benefits of influenza vaccination in elderly people, an ongoing controversy. Lancet Infect. Dis.7(10), 658–666 (2007).
   PubMed Web of Science ®Google Scholar
• Jefferson T, Di PC, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst. Rev.2, CD004876 (2010).
   Google Scholar
• Poland GA, Jacobson RM, Ovsyannikova IG. Influenza virus resistance to antiviral agents, a plea for rational use. Clin. Infect. Dis.48(9), 1254–1256 (2009).
   PubMed Web of Science ®Google Scholar
• Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005, a cause for concern. Lancet366(9492), 1175–1181 (2005).
   PubMed Web of Science ®Google Scholar
• Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States. JAMA295(8), 891–894 (2006).
   PubMed Web of Science ®Google Scholar
• Update, influenza activity – United States, September 28–November 29, 2008. MMWR Morb. Mortal. Wkly Rep.57(49), 1329–1332 (2008).
   PubMedGoogle Scholar
• Keitel WA, Atmar RL, Cate TR et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch. Intern. Med.166(10), 1121–1127 (2006).
   PubMed Web of Science ®Google Scholar
• Couch RB, Winokur P, Brady R et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine25(44), 7656–7663 (2007).
   PubMed Web of Science ®Google Scholar
• Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS. Inactivated vaccines. 1. Volunteer studies with very high doses of influenza vaccine purified by zonal ultracentrifugation. Postgrad. Med. J.49(569), 152–158 (1973).
   PubMed Web of Science ®Google Scholar
• Podda A. The adjuvanted influenza vaccines with novel adjuvants, experience with the MF59-adjuvanted vaccine. Vaccine19(17–19), 2673–2680 (2001).
   PubMed Web of Science ®Google Scholar
• Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults, a randomized controlled trial. J. Infect. Dis.198(5), 650–658 (2008).
   PubMed Web of Science ®Google Scholar
• Gorse GJ, O’Connor TZ, Young SL et al. Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease, a VA cooperative study. Vaccine21(17–18), 2133–2144 (2003).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Mattison HR, Dumyati G et al. Protective efficacy of combined live intranasal and inactivated influenza A virus vaccines in the elderly. Ann. Intern. Med.117(8), 625–633 (1992).
   PubMed Web of Science ®Google Scholar
• Rudenko LG, Arden NH, Grigorieva E et al. Immunogenicity and efficacy of Russian live attenuated and US inactivated influenza vaccines used alone and in combination in nursing home residents. Vaccine19(2–3), 308–318 (2000).
   PubMed Web of Science ®Google Scholar
• de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine26(1), 119–127 (2007).
   PubMed Web of Science ®Google Scholar
• Tosh PK, Poland GA. Emerging vaccines for influenza. Expert Opin Emerg. Drugs13(1), 21–40 (2008).
   PubMed Web of Science ®Google Scholar
• Loeb M, Russell ML, Moss L et al. Effect of influenza vaccination of children on infection rates in Hutterite communities, a randomized trial. JAMA303(10), 943–950 (2010).
   PubMed Web of Science ®Google Scholar
• Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. Randomized, double-blind controlled Phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis.200(2), 172–180 (2009).
   PubMed Web of Science ®Google Scholar
• Cate TR, Rayford Y, Nino D et al. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine28(9), 2076–2079 (2010).
   PubMed Web of Science ®Google Scholar
• Poland GA. Pharmacology, vaccinomics, and the 2nd golden age of vaccinology. Clin. Pharmacol. Ther.82(6), 623–626 (2007).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Uyeki TM, Broder K et al. Prevention and Control of Influenza with vaccines, recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm. Rep.59(RR-8), 1-62 (2010).
   PubMedGoogle Scholar
• Jacobson RM, Adegbenro A, Pankratz VS, Poland GA. Adverse events and vaccination – the lack of power and predictability of infrequent events in pre-licensure study. Vaccine19, 2428–2433 (2001).
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response, The role of immunogenetics and the emerging field of vaccinomics. Clin. Pharmacol. Ther.82(6), 653–664 (2007).
   PubMed Web of Science ®Google Scholar